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INTRODUCTION:
Knowledge of genetic changes that occur in cancer cells should ultimately facilitate individualized approaches to cancer treatment. However, methods to systematically profile cancers for relevant genetic changes in the clinical setting remain underdeveloped. The overarching goal of this proposal is to use cutting-edge genomic technology (massively parallel sequencing) in patients with breast cancer to identify genetic determinants of tumor behavior that may inform clinical decision-making. Two unmet clinical challenges in breast cancer motivate this approach. The first is the need for improved biological understanding of early stage estrogen-receptor positive (ER+) tumors with a high risk of recurrence. Systematic genetic profiling of early stage ER+ tumors may identify specific subsets of breast cancer and predict which patients are most likely to relapse. Second, there is a clear need for novel therapeutic strategies in metastatic breast cancers that have become resistant to standard therapies. Systematic genetic characterization of these resistant cancers might teach us about new therapeutic strategies or guide the development of targeted drug combinations that may help to overcome cancer drug resistance. The aims of this study were to profile a clinically annotated cohort of 150 ER+ breast tumors to look for genetic differences in both early-recurring and laterecurring tumors. In addition, we sought to prospectively profile at least 50 patients with advanced breast cancer in order to study the impact of our approach in a setting that may ultimately inform clinical decision-making. 
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OVERALL PROJECT SUMMARY: AIM #1: To perform genomic profiling across a clinically annotated cohort of ER+ breast tumors
The goal of this Aim was to establish a breast-cancer focused mutation profiling platform and use it to study an annotated collection of tumor samples from patients with ER+ breast cancers. During the course of this award, we successfully designed and constructed a targeted sequencing platform that can be used on FFPE tumor samples. This platform targets all known breast cancer related genes identified in large sequencing studies of breast cancer samples from the past several years, including several novel genomic alterations that we and others have recently identified in ER+ breast cancer samples. This platform is to be deployed on a cohort of tumor samples from patients with ER+ breast cancer who have had early recurrence, late recurrence, or no recurrence at 10 years. Sequencing of these tumor samples has been delayed due to limited funding; however, this is expected to proceed in the near future.
AIM 1A: To develop a breast cancer-focused massively parallel sequencing platform for FFPE samples 4 large sequencing studies (published in Nature in 2012) used whole exome and/or whole genome sequencing to catalogue the landscape of genomic alterations in primary, treatment-naïve breast cancers [1] [2] [3] [4] . In total, 819 primary breast cancers were sequenced across these 4 studies, of which 529 were ER+ ( Table 1) . A fifth study by Matthew Ellis and colleague 5 reported the sequencing of 77 pretreatment tumor biopsies (46 whole genomes and 31 whole exomes) from patients with luminal breast cancer treated with a neoadjuvant aromatase inhibitor. This study was designed to identify genomic biomarkers that may predict response or intrinsic (de novo) resistance to endocrine therapy. Based on Ki67 levels in the surgical specimens, samples were stratified into AI-sensitive (Ki67 < 10%, n = 48) and AI-resistant samples (Ki67 > 10%, n = 29). Mutations in MAP3K1 and possibly GATA3 were associated with AI-sensitivity, while TP53 mutations were associated with the AI-resistance. In the aggregate, these five studies have shed tremendous light onto the genomics of primary treatment-naive breast tumors.
As described in our original research proposal, we developed an enriched set of genes including these new significantly altered genes identified in breast cancer, as well as numerous other novel cancer genes that have recently been identified. In total, this design included all of the exons from 435 genes, selected introns to identify translocations from 22 genes, more extensive tiling across the entirety of 23 genes, and the promoter of the TERT gene. The resultant list of genomic coordinates were optimized and a set of baits were designed and synthesized. We completed testing and implementing of this platform, as described in our original research proposal.
More recently, we identified several novel alterations in in ER+ breast tumors, including translocations in ESR1, the gene that encodes the estrogen receptor (Wagle, Garraway, and Arteaga, unpublished results). Given the potential importance of ESR translocations in ER+ breast cancer, we then further modified our bait design to include genomic coordinates across select introns in ESR1. In addition, two papers from the Broad Institute published in Nature in 2013 highlighted several novel cancer genes not previously identified as significant in cancer 6, 7 . All of these alterations were also added to our targeted sequencing panel design, and a 2 nd iteration (v2.0) was then developed. This v2.0 targeted sequencing panel is particularly well suited to profiling ER+ breast tumors.
TASKS:
• Design and optimization of breast-cancer specific platform (Month 1 -Month In this aim, we proposed to use our breast-cancer focused platform to profile a cohort of early stage ER+ breast tumors that have recurred after adjuvant therapy, including patients with late relapse, early relapse, and no relapse at 10 years. IRB approval was obtained to obtain and sequence these samples, and approval from the DFCI Breast Cancer User Committee for use of these tissues was also obtained. Due to delays in the sequencing platform development, user committee approval, and limitations of funding sources to perform the sequencing on all 150 samples, this aim has not yet been completed. Additional funding sources are presently being obtained, and, once funding is in place, sequencing of these tumors samples will commence. In this Aim, we proposed to apply massively parallel sequencing to patients with advanced breast cancer. The goal here was to study the feasibility of our approach in a setting that may ultimately inform clinical decision-making. This will serve as a proof-of-principle for how genomics could be used prospectively for cancer precision medicine -to uncover somatic genetic changes that impact the treatment and prognosis of patients with breast cancer. Because of the delay in implementing the new targeted sequencing platform, we established a more comprehensive platform that incorporates whole exome sequencing and transcriptome sequencing (RNASeq) in patients with advanced breast cancer. This platform includes all targets in the v2.0 targeted sequencing panel described above, but is more comprehensive in that it can detect mutations, insertions/deletions, copy number alterations, and translocations in all genes in the genome, as well as genome-wide expression.
Towards the beginning of the grant term, we established a pipeline for prospective whole exome sequencing from FFPE tumor samples to support clinical decision making (and clinical trial enrollment) for appropriately consented patients with advanced cancers at the Dana-Farber Cancer Institute (DFCI) known as CanSeq. We initially conducted a pilot study on 16 patients that enabled optimization of various aspects of our emerging clinical sequencing pipeline, including sample acquisition, DNA extraction, sequencing, and analysis. The somatic and germline alterations were analyzed using a heuristic algorithm called PHIAL. This algorithm applies a categorization framework that incorporates the degree of actionability and level of evidence for that action. A similar algorithm was also been developed for germline alterations. We also developed a customized report that streamlines the results of these algorithms for presentation to a Cancer Genomics Evaluation Committee, a multi-disciplinary "genomics tumor board" whose purpose was to make decisions about the interpretation and clinical actionability of somatic and germline alterations. Somatic analysis of the first 16 patients demonstrated at least one plausibly actionable somatic alteration linked to an approved or experimental therapy in 15 out of 16 cases. This work was published in Nature Medicine in 2014 (Van Allen, .
Building on the foundation established by CanSeq, our prospective sequencing approach for patients with metastatic breast cancer has continued to evolve over the past few years. Patients at DFCI with metastatic ER+ breast cancer are asked to enroll on an IRB-approved metastatic breast cancer biopsy protocol (#05-246). Under this protocol, 3-6 frozen core biopsies are collected from metastatic lesions and are available for genomic testing. For all patients, we simultaneously obtain a tube of blood as a source of germline DNA. Thus, this protocol allows prospective whole exome and transcriptome sequencing of metastatic biopsies from patients with advanced ER+ breast cancer -both for retrospective analysis and prospective return of results, when appropriate.
In 2014, during the course of this award, I transitioned from a post-doctoral fellow in Levi Garraway's laboratory to an independent faculty member in the Department of Medical Oncology at Dana-Farber Cancer Institute. In this new independent faculty role, I am a member of the new Dana-Farber/Brigham and Women's/Broad Institute Center for Cancer Prevision Medicine (CCPM). As part of the CCPM, I developed a novel infrastructure and workflow to conduct this research project, based on the experiences gained over the past few years. This is detailed in Figure 1 . This workflow enables the acquisition of multiple clinical and research biopsies from patients with metastatic breast cancer with the return of relevant clinical information (including genomic sequencing) to the clinician and patient. The remaining tissues are available for genomic and molecular analyses, as shown in Figure 1 . In this way, this new workflow serves both Aim 2A and 2B. Prospective enrollment using this new workflow began in June 2015.
AIM 2A: To assess the clinical impact of prospective genomic profiling in advanced breast cancer Under the new Center for Cancer Precision Medicine workflow, described above (Figure 1) , we have collected 111 metastatic biopsies from 105 patients with ER+ metastatic breast cancer. 6 cores were taken per biopsy on average (range 1-12). The number of biopsies with sufficient material for each test and success rates is shown in Figure 2 . In 3/94 biopsies (3%), pathology found a tumor type other than breast cancer. Of the remaining testable samples, 10% changed ER or HER2 status. Both of these findings highlight that in more than 10% of patients with advanced breast cancer, the routine pathologic evaluation of metastatic biopsies has clinically relevant implications. Physicians have now begun to act on this information. As shown in Figure 3 , physicians have the opportunity to use the results they receive to enroll patients on several clinical trials that use these alterations as entry criteria. We are in the process of developing additional trials to be included in the list of potential options. As an example, one patient with resistant metastatic breast cancer was found to have an ERBB2 activating mutation in her metastatic tumor biopsy. This led her physician to enroll her on a clinical trial of neratinib and fulvestrant, which requires an activating ERBB2 mutation for enrollment. She has had an excellent response to therapy, and continues on this clinical trial at present (see Figure 4) . In summary, we have shown that metastatic biopsy program for cancer precision medicine in breast cancer is feasible, with >90% of biopsies yielding sufficient tissue for pathology, receptors, and targeted sequencing. Multiple clinically relevant genomic and molecular alterations are identified in metastatic biopsies -with implications for choice of next therapy, clinical trial eligibility, and novel drug targets. This includes identifying a cancer other than breast cancer (3%), a change in ER or HER2 status (10%), and somatic alterations that are entry criteria for clinical trials of targeted therapies (>70%). We plan to continue collection of serial biopsies from enrolled patients, and utilize clinically relevant pathological, genomic, and molecular information for clinical decision-making and trial enrollment.
• The goal of this aim was perform whole exome sequencing in breast cancer patients who develop resistance to targeted therapies (e.g., endocrine therapies, anti-Her2 therapies, PI3K inhibitors, mTOR inhibitors) in order to identify novel resistance mechanisms. In addition to the 111 biopsies above, we were able to obtain an additional 72 metastatic tumor biopsies and matched blood samples that were obtain from Dana-Farber patients between 2006 and 2014, including 27 biopsies that have been collected since the start of this grant term.
Of these 183 metastatic biopsies, we have been able to obtain matched pre-treatment primary tissues from 77 patients, resulting in 77 "trios" of primary, metastatic, and normal tissues from the same patient ( Figure  5) .
Whole exome and transcriptome sequencing of all tissues from 63 of these trios has now been completed, and analysis is underway. We are also in the process of obtaining and sequencing the pretreatment samples from the remaining patients, and expect to ultimately have pretreatment and post-resistance analysis on at least 100 patients with ER+ metastatic breast cancer.
While systematic analysis of these trios is currently underway, to date we have completed a preliminary landscape analysis of whole exome sequencing from 100 endocrine-resistant metastatic biopsies. This analysis highlights several genes that are recurrently altered at different Figure 6 . Analysis of matched pre-treatment and resistant tumor biopsies. Of the 183 patients described above, we have been able to obtain matched pre-treatment primary tissues from 77 patients to date, resulting in "trios" of primary, metastatic, and normal tissues from the same patient. rates than in primary breast cancer (Figure 7) . In many cases, these genes are acquired in the resistant tumors and not detected in the corresponding pre-treatment biopsies. For example, Figure 8 illustrates a patient who acquires several genomic alterations that can result in resistance to endocrine therapy, including loss of ER and loss of RB1. Several additional resistance candidates have been identified in this initial analysis. The preliminary results for this study was presented at the 2016 ASCO Annual Meeting (Wagle et al, 2016) . A manuscript is currently in preparation.
In addition to this study on ER+ metastatic breast cancer, we had access to metastatic tumor biopsies collected from patients enrolled on a phase II study evaluating the combination of lapatinib and trastuzumab in patients with metastatic HER2+ breast cancer. The total study accrual was 116 patients and a baseline tumor biopsy was required at time of study entry.
By design, patients had varying degrees of prior trastuzumab exposure. We performed deep whole exome sequencing (WES) on metastatic frozen tumors and matched normal tissue from 65 patients plus 54 matched archival FFPE primary samples. The two most significant recurrently mutated genes in this cohort were PIK3CA (n=22; 34%) and TP53 (n=36; 55%). As shown in Figure 9 , compared to 120 primary, treatment-naïve HER2+ tumors sequenced in the TCGA study, there was no significant difference in the incidence of point mutations and indels in TP53 and PIK3CA (55% and 34%, respectively). However, the incidence of ERBB2 (HER2) mutations was significantly increased (14% vs 2%, p = 0.002). There was no significant difference in the mutation rates in ERBB3, ERBB4, and EGFR. HER2 mutations have previously been identified in ~2% of primary HER2-cancers and <2% of primary HER2+ cancers (CBio portal). In our study, we identified a somatic HER2 mutation in 9 out of 65 metastatic biopsies (14%), 5 of which were in the kinase domain ( Figure 5 ). The HER2 L755S mutation (found in 3 patients) is a well-described activating mutation in HER2 that results in resistance to lapatinib and sensitivity to irreversible inhibitors (e.g. neratinib). The remaining 2 kinase domain mutations have not been described previously. They were present at low allelic fractions, both in patients who received prior trastuzumab. Characterization of these mutations is currently underway. 4 additional patients, 2 of whom received prior trastuzumab, had uncharacterized mutations in other domains of HER2 at low allelic fractions Additional recurrently mutated genes occur at much lower frequencies and are being confirmed. In addition, an analysis to identify genes that may contribute to resistance to trastuzumab is being conducted by comparing matched metastatic and primary biopsies from the 46 patients who received prior anti-Her2 therapy prior to the metastatic biopsy. The results for these studies on HER2+ metastatic breast cancer patients were presented in a Poster Highlights session at the 2014 ASCO Annual Meeting (Wagle et al, 2014b ) and in a Poster Highlights session with an oral presentation at the 2014 San Antonio Breast Cancer Symposium (Wagle et al, 2014b) . A manuscript is currently in preparation.
In summary, we have performed comprehensive next-generation sequencing on more than 130 sets of metastatic biopsies and matched pretreatment biopsies from patients with metastatic breast cancer. Going forwards, we plan to continue our analysis of whole exome and transcriptome data from these cohorts. We will integrate this sequencing data with clinical information to identify potential mechanisms of resistance to specific agents, and then perform functional and mechanistic testing of key alterations to further elucidate the landscape of resistance mutations in metastatic breast cancer.
• Whole exome sequencing of patients with acquired resistance to targeted therapies (Month 9 -Month 36): COMPLETE
MILESTONES:
• Whole exome sequencing on first 3-6 patients with acquired resistance completed by Month 16: COMPLETE • Whole exome sequencing of at least 15 patients with acquired resistance completed by Month 33: COMPLETE Figure 9 . HER2 mutations identified in HER2+ metastatic breast cancer biopsies.
KEY RESEARCH ACCOMPLISHMENTS:
• Development of a novel targeted sequencing platform that includes ~450 genes that are significantly altered in breast cancer and other cancers, including novel unpublished alterations that we have recently identified in ER+ breast cancers • Development of a prospective whole exome sequencing pipeline that includes sequencing from FFPE samples, analysis, curation, and interpretation of clinically relevant somatic and germline alterations, discussion of key findings by the Cancer Genome Evaluation Committee, and return of results to physicians and patient (Van Allen o PIK3CA and TP53 were significantly recurrently mutated in these tumors, at the same rate as in primary, treatment-naïve HER2+ breast cancer o The prevalence of PIK3CA and TP53 mutations was similar in the metastatic samples from those patients who received prior trastuzumab and those who were trastuzumab naïve, though some metastatic biopsies in patients who received prior trastuzumab had mutations of interest not detected in the corresponding primaries o Somatic HER2 mutations in patients with HER2+ MBC treated seem to occur at a higher rate than in primary HER2+ breast cancer, and may be involved in resistance to trastuzumab and lapatinib
CONCLUSION:
To date, we have made significant progress on this research project.
Although not yet fully completed, this work has already provided new knowledge that informs the development of novel treatment strategies in breast cancer. For Aim 1, we expect to utilize the targeted sequencing panel we have developed to profile 150 early stage ER+ breast cancers in the near future. For Aim 2, we have completed our stated goal of performing and returning whole exome and targeted sequencing on 50 patients with advanced breast cancer, and have extended the cohort to more than 80 patients. We have also collected and sequencing metastatic biopsies and matched pretreatment samples on our stated goal of at least 15 patients, and have extended this to more than 130 patients. We expect to complete the analysis on these cohorts shortly. Once complete, we hope to be able to better determine how best to use targeted therapies in advanced breast cancer, and to develop novel strategies to overcome resistance mechanisms. 
INVENTIONS, PATENTS AND LICENSES:
Nothing to report.
REPORTABLE OUTCOMES:
Nothing to report. 
OTHER ACHIEVEMENTS
TRAINING AND PROFESSIONAL DEVELOPMENT:
I continue to be advised by an exceptional group of mentors to help guide me in my research and my career development. My primary scientific mentor is Dr. Levi Garraway, a visionary physician-scientist with an extraordinary scientific track record who has served as an outstanding personal and professional role model. I have also continued to be mentored by a committee comprised of world-class experts in breast cancer translational research and cancer genomics, who have provided invaluable guidance over the course of this award. My training has also been enhanced by my training environment. I have had the opportunity to attend multiple weekly and monthly seminars and courses as well as present my work in them. In addition, I have had the opportunity to attend numerous scientific meetings over the past few years, including the San
